Mast Cell Activation Syndrome

If you have landed on this page, you have probably already done a lot of reading on mast cell activation syndrome. Some of it was helpful. Most of it was alarming. The MCAS conversation online swings hard between "this is rare and you almost certainly do not have it" and "this explains every weird symptom you have ever had." Neither extreme is useful when you are the one trying to feel better.

What follows is the version I walk through with patients in clinic. What MCAS is. How it gets diagnosed, and why two sets of criteria are still in circulation. What sets off a flare. The stabilization sequence I reach for first. And the parts of recovery that get less attention than they deserve: the gut, the hormones, and the nervous system. Each section links to deeper writing if you want to keep going.

What MCAS Is, and the Histamine Bucket#

Mast cells are immune cells that live in your tissues. They sit in the gut lining, the skin, the sinuses, around blood vessels, and they release chemical messengers when they sense a threat. Histamine is the most famous of those messengers. Mast cells also release tryptase, prostaglandins, leukotrienes, and a long list of cytokines.

In a healthy system, that release is appropriate to the threat. In MCAS, mast cells become hyperreactive. They release too much, too easily, in response to triggers that should not provoke a reaction.

Researchers usually divide MCAS into three forms. Primary MCAS is a clonal mast cell disorder, often involving a KIT mutation. Secondary MCAS is mast cells overreacting in the context of another driver, such as an allergic disorder. Idiopathic MCAS is mast cells overreacting with no clear underlying cause. Most of what I see in clinic is the idiopathic and secondary type. Symptoms run across organ systems: skin reactions, gastrointestinal symptoms, flushing, brain fog, palpitations, anxiety, sinus involvement, and reactions to foods, scents, or temperatures that did not used to bother you.

The simplest model I use to explain why symptoms appear out of proportion to the trigger is the histamine bucket. Picture a sink. The faucet is histamine, released by your mast cells, produced by gut bacteria, and eaten in food. The drain is your body's ability to break histamine down, mostly through the enzyme diamine oxidase (DAO) in the gut and histamine N-methyltransferase elsewhere. In a regulated system, the faucet turns on briefly when needed, the drain clears it, and the level stays steady.

In histamine intolerance, the faucet is roughly normal but the drain is sluggish, usually because of impaired DAO activity. Histamine accumulates over hours and days. Eventually a small additional input pushes the bucket over the rim. A glass of wine. A piece of leftover chicken. A rough night of sleep. The reaction looks disproportionate to the trigger because the bucket was already three-quarters full.

In MCAS, the faucet is the problem. Mast cells release histamine and the other mediators too readily, often in response to non-allergic triggers. The drain may also be impaired, which is why MCAS and histamine intolerance frequently coexist. Both end the same way (symptoms when the bucket overflows), but the leverage points for treatment are different.

How MCAS Gets Diagnosed#

This is where MCAS gets contentious, and it is worth understanding why. There are currently two parallel diagnostic frameworks in use [1, 2, 3].

Consensus-1, favored by most allergy and immunology specialists, requires three things: a typical clinical pattern of episodic, multi-system symptoms; a documented increase in serum tryptase of at least 20% above baseline plus 2 ng/mL within one to four hours of a flare; and response to mast-cell-targeted therapy. The tryptase requirement is strict, which makes the diagnosis specific. If you meet it, you almost certainly have MCAS. Yet it also means a lot of people with MCAS never qualify, since catching tryptase during a flare is logistically difficult and tryptase rises only modestly even in significant mediator release.

The three Consensus-1 criteria (all required):

• Typical clinical pattern of episodic, multi-system mast cell mediator symptoms involving 2 or more organ systems
• Documented serum tryptase rise of at least 20% above baseline plus 2 ng/mL, measured within 1 to 4 hours of an acute episode
• Symptomatic response to mast-cell-targeted therapy (antihistamines, mast cell stabilizers)

Consensus-2, favored by many integrative and naturopathic clinicians and a portion of the allergy community, keeps the major criterion of multi-system symptoms but allows several minor criteria to support the diagnosis. One of those minor criteria is documented response to mediator-directed therapy: antihistamines, mast cell stabilizers. Under Consensus-2, you do not have to provoke a flare to capture a tryptase number. Response to treatment, in the context of a fitting clinical picture, is itself diagnostic.

The Consensus-2 criteria (the major criterion plus at least one minor):

Major criterion:

• A constellation of clinical complaints attributable to pathologically increased mast cell mediator activity, involving 2 or more organ systems

Minor criteria (any one alongside the major):

• Multifocal or disseminated dense infiltrates of mast cells in bone marrow or other extracutaneous tissue on biopsy
• Abnormal mast cell morphology (spindle-shaped or hypogranulated) on biopsy
• Aberrant mast cell expression of CD2 and/or CD25 by immunohistochemistry or flow cytometry
• Detection of a KIT D816V mutation in extracutaneous tissue
• Above-normal levels of mast cell mediators in blood or urine (tryptase, N-methylhistamine, prostaglandin D2 or its 11β-PGF2α metabolite, leukotriene E4, chromogranin A, or heparin)
• Symptomatic response to mast-cell-targeted therapy (antihistamines, mast cell stabilizers, leukotriene blockers)

Both frameworks are reasonable. Which one your clinician uses matters because Consensus-1 underdiagnoses, while Consensus-2 risks overdiagnosis. The question I usually ask with patients is: what do you need a formal diagnosis to do? If you need it for insurance to cover specific medications, or for a disability application, the formal Consensus-1 workup is worth pursuing. If we are working symptomatically, trying to figure out whether your body responds to mast cell support and what your triggers are, then a careful trial of mediator therapy under Consensus-2 is often the more humane path. You do not have to put yourself through a flare to get a number.

What Sets Off a Flare#

Most people expect food to be the main trigger. Food is part of the picture, but it is rarely the whole story. The triggers I work through with patients usually fall into four categories.

Foods and beverages. High-histamine foods (aged cheeses, fermented foods, cured meats, leftovers, alcohol, especially red wine and beer), histamine liberators (citrus, strawberries, tomatoes, chocolate), and DAO-blocking compounds [4, 5]. The list looks overwhelming on first read, and most patients do not need to avoid everything on it. Bucket position matters more than absolute exclusion.

Hormones. Estrogen activates mast cells and suppresses DAO. Many women notice that symptoms cycle with their menstrual phase, worsen in perimenopause, or flare on certain forms of hormonal contraception. Progesterone tends to be stabilizing. The luteal phase and ovulation are common flare windows.

Stress and nervous-system state. Mast cells carry receptors for corticotropin-releasing hormone (CRH), the brain's stress signal. Acute and chronic stress directly activate mast cells, separate from any food or chemical exposure. This is also why an anticipatory worry about reacting can itself produce a reaction. It is not "in your head" in the dismissive sense. It is a physiological pathway with its own mechanism.

Comorbid conditions. Postural orthostatic tachycardia syndrome (POTS), Ehlers-Danlos syndrome and other hypermobility spectrum disorders, and MCAS travel together often enough that they have been described as a clinical triad [6]. SIBO and gut dysbiosis amplify histamine load through bacterial production. Mold exposure, chronic infections, and post-viral states can all serve as the original trigger that pushed an immune system into hyperreactivity.

When patients come in saying they cannot figure out what is setting them off, the answer is usually that several of these are stacking. The bucket fills from multiple taps.

The Stabilization Sequence#

Treatment for MCAS works best when it is sequenced. You cannot do gut-healing work on a body that is in a constant reactive state, since the reactivity itself blocks deeper progress. Here is the order I generally use.

First, calm the reaction. When symptoms are severe or coming in cycles, antihistamines are the right starting point. First-generation antihistamines like hydroxyzine or diphenhydramine and second-generation antihistamines like cetirizine, loratadine, or fexofenadine all stabilize mast cell activity, with different profiles. Daily H1 blockade is often combined with H2 blockade (famotidine) to cover both receptor families. Mast cell stabilizers like cromolyn sodium are sometimes added when antihistamines alone are not enough. This is the "give the body a break" step. Using medications here is not a failure. It is the foundation that lets the slower work proceed.

Second, layer in the supportive nutrients. Quercetin is the most studied plant-derived mast cell stabilizer. In cell-based work and a small clinical trial, quercetin matched or exceeded cromolyn at inhibiting cytokine release from human mast cells [7]. Vitamin C, luteolin, and bromelain are also commonly used. Tolerance varies, and many MCAS patients are sensitive to supplement additives, so single-ingredient or minimally-formulated products are usually better tolerated. Quercetin and luteolin are also metabolized through the COMT enzyme, the same pathway that clears catecholamines and estrogen. People with COMT variants sometimes do better at lower doses or with a different stabilizer.

Third, support DAO. A DAO supplement taken before histamine-heavy meals can blunt the response to dietary histamine [4, 8]. I think of it the way I think of pancreatic enzymes in chronic pancreatitis: useful as a temporary brace while you work on restoring the body's own production. The longer-term goal is to repair the gut tissue that produces DAO endogenously, not to rely on the supplement indefinitely.

Fourth, only after the first three are stable, do the deeper work. Address the gut, the hormones, the nervous system, and any contributing infections or exposures. Trying to do this work in a body that is still in reactive crisis tends to fail, and the failure is often misread as "the protocol does not work for me."

Diet, Without Becoming a Diet#

A low-histamine diet is the most-discussed dietary intervention for MCAS and histamine intolerance, and the evidence supports it as a useful tool. Patients on histamine-reduced diets generally report symptom improvement, and one observational study found that serum DAO activity rose in line with diet adherence [9, 10]. There is a practical caveat. Published low-histamine food lists vary enormously, and not every food on every list is genuinely high in histamine [4]. Excluding too much, for too long, almost always backfires. Gut diversity narrows. Social life shrinks. The relationship with food gets harder to repair than the original symptoms.

The way I run a low-histamine trial with patients is short, structured, and reversible. Two to three weeks of careful eating: fresh proteins cooked the day they are bought, well-tolerated cooked vegetables, fresh-baked grains, and avoidance of the obvious heavy hitters (aged cheese, fermented foods, leftovers, alcohol, processed meats). Two or three weeks is usually enough to know whether food histamine is meaningfully part of your picture. From there, foods come back in one at a time, paying attention to where the bucket sits. The goal is the smallest workable list of foods to avoid, not the largest.

The Gut Connection#

Most of the body's DAO is produced in the small intestine, which means gut health and histamine clearance are deeply linked. Histamine intolerance, in particular, may originate in the gut. When intestinal mucosa is inflamed, dysbiotic, or compromised, DAO production drops and histamine that should be degraded locally instead reaches the bloodstream [11].

This is also where the SIBO and MCAS overlap shows up. Some gut bacteria produce histamine themselves, so an overgrowth of histamine-producing organisms in the small intestine adds to the bucket from the inside. Inflammatory conditions like inflammatory bowel disease and irritable bowel syndrome appear to involve dysregulated histamine signaling as part of the picture [12]. A randomized controlled trial of low-FODMAP eating in IBS patients found urinary histamine dropped roughly eightfold compared to high-FODMAP, which is one of the more interesting bridges between gut-directed dietary intervention and the histamine economy [13].

If your MCAS picture has a strong gut component (bloating, irregular stools, abdominal discomfort, or food reactions that map onto fermentable carbohydrates), the gut work is part of the long-term plan, not an afterthought. The SIBO and gut-motility hub covers this in more depth.

Hormones, Cycles, and Why Symptoms Move#

Many of my patients can predict their flare windows by their cycle, and there is a mechanism behind that. Mast cells carry estrogen receptors and are activated by estrogen exposure. Estrogen also down-regulates DAO. Progesterone, by contrast, tends to stabilize mast cells. So the high-estrogen windows of the cycle (ovulation, the late follicular phase, and the days before menses) often correspond to flare risk, while the mid-luteal window with rising progesterone can be calmer.

This pattern is also why MCAS frequently presents or worsens at hormonal transitions: puberty, postpartum, perimenopause. Hormonal contraception can go either way. Progestin-dominant methods are often well tolerated. Combined estrogen-containing methods sometimes intensify symptoms. Copper IUDs are non-hormonal, but copper itself plays a role in DAO activity, so reactions there are individual.

The point is not that hormones are good or bad. If your symptoms move in time with your cycle, that pattern is mechanistic, and the treatment plan should account for it. Sometimes that looks like timing higher-stabilizer doses to the high-risk window. Sometimes it means working on estrogen metabolism more directly. Sometimes it means reconsidering a contraceptive that is clearly making things harder.

Stress and the Long Loop#

I want to address stress carefully, since it is the place where MCAS conversations most often go wrong. Patients hear "stress can trigger MCAS" and reasonably hear it as a dismissal: your symptoms are anxiety. That is not what the mechanism says. Mast cells carry receptors for corticotropin-releasing hormone, the brain's stress signal, and CRH directly activates mast cell degranulation. Stress is a physical trigger, not a psychological dismissal.

The clinical implication is that prolonged stress (major life stress, trauma history, chronic illness itself) keeps the immune system in a low-grade state of vigilance. Mast cells fire more readily. The body interprets ordinary stimuli as threats. The experience of having reactions is itself stressful, which feeds back into the loop. People can get stuck in a cycle of reacting and then bracing for the next reaction, with both pieces driving symptoms.

Working with the nervous system is not separate from MCAS treatment. It is part of it. Paced breathing, vagal tone work, somatic practices, trauma-informed therapy where indicated, and basic safety-of-environment changes all belong in the plan. The goal is not to talk you out of having mast cells. It is to lower the baseline threat signal so that your immune system has room to settle.

What Healing Looks Like#

People ask whether MCAS can be cured. The honest answer is that for most people, "cure" is the wrong word. What we are aiming at is stability: predictable symptoms instead of chaotic ones, fewer and less intense flares, recognizable triggers, and a life that is no longer organized around reactivity.

For some patients this looks like full remission of symptoms with maintenance support. For others it looks like a quiet baseline punctuated by occasional flares that resolve quickly. Most land somewhere in between, and most can get there with a methodical, layered approach over months, not weeks or years.

If you are at the beginning of this work, the most useful thing you can do is start somewhere small and stay consistent. The bucket lowers slowly. It also stays lowered, once you understand what it is responding to.

---

If you want a structured walk-through of MCAS stabilization, the same order I take patients through in clinic, the MCAS Stabilization Roadmap is a free guide that covers the first phase of the work. The full course, Mastering MCAS, goes deeper into triggers, lab interpretation, and protocol design.

References#

1. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global "consensus-2." Diagnosis (Berl). 2020;8(2):137-152. doi:10.1515/dx-2020-0005
2. Weiler CR, Austen KF, Akin C, et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019;144(4):883-896. doi:10.1016/j.jaci.2019.08.023
3. Valent P, Akin C, Bonadonna P, et al. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133.e1. doi:10.1016/j.jaip.2019.01.006
4. Comas-Basté O, Sánchez-Pérez S, Veciana-Nogués MT, Latorre-Moratalla M, Vidal-Carou MC. Histamine Intolerance: The Current State of the Art. Biomolecules. 2020;10(8):1181. doi:10.3390/biom10081181
5. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85(5):1185-1196. doi:10.1093/ajcn/85.5.1185
6. Blitshteyn S. Dysautonomia, Hypermobility Spectrum Disorders and Mast Cell Activation Syndrome as Migraine Comorbidities. Curr Neurol Neurosci Rep. 2023;23(11):769-776. doi:10.1007/s11910-023-01307-w
7. Weng Z, Zhang B, Asadi S, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One. 2012;7(3):e33805. doi:10.1371/journal.pone.0033805
8. Hrubisko M, Danis R, Huorka M, Wawruch M. Histamine Intolerance: The More We Know the Less We Know. A Review. Nutrients. 2021;13(7):2228. doi:10.3390/nu13072228
9. Lackner S, Malcher V, Enko D, Mangge H, Holasek SJ, Schnedl WJ. Histamine-reduced diet and increase of serum diamine oxidase correlating to diet compliance in histamine intolerance. Eur J Clin Nutr. 2019;73(1):102-104. doi:10.1038/s41430-018-0260-5
10. Jochum C. Histamine Intolerance: Symptoms, Diagnosis, and Beyond. Nutrients. 2024;16(8):1219. doi:10.3390/nu16081219
11. Schnedl WJ, Enko D. Histamine Intolerance Originates in the Gut. Nutrients. 2021;13(4):1262. doi:10.3390/nu13041262
12. Valent P, Akin C, Nedoszytko B, et al. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int J Mol Sci. 2020;21(23):9030. doi:10.3390/ijms21239030
13. McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66(7):1241-1251. doi:10.1136/gutjnl-2015-311339